Welcome to our dedicated page for Silo Pharma news (Ticker: SILO), a resource for investors and traders seeking the latest updates and insights on Silo Pharma stock.
Overview
Silo Pharma Inc. is a developmental stage biopharmaceutical company that develops innovative therapeutics by merging traditional formulations with advanced psychedelic research. The company is dedicated to addressing underserved conditions including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. Through its unique approach, Silo Pharma focuses on both traditional and psychedelic treatment modalities to provide novel solutions where unmet medical needs persist.
Therapeutic Programs and Drug Delivery Systems
Silo Pharma is actively progressing a broad portfolio of therapeutic programs, each aimed at targeting specific medical indications:
- SPC-15: An intranasal serotonin 5-HT4 receptor agonist designed for treating post-traumatic stress disorder (PTSD) and stress-induced anxiety disorders. Leveraging biomarker-driven research, SPC-15 utilizes a non-invasive delivery method for rapid therapeutic onset.
- SP-26: A ketamine-based, time-release polymer implant developed to manage chronic pain conditions such as fibromyalgia. This innovative implant is designed to provide consistent, dosage-controlled pain relief through a minimally invasive subcutaneous procedure.
- Additional programs include preclinical assets targeting CNS disorders such as Alzheimer’s disease and multiple sclerosis, which further underscore the company’s comprehensive approach to neurological challenges.
Research Collaborations and Intellectual Property
Silo Pharma conducts its research and development through strategic collaborations with world-class medical research partners and universities. By partnering with renowned institutions, the company ensures robust scientific validation and leverages cutting-edge research in its clinical development pathways. An important component of its business model is a focused intellectual property strategy that reinforces patent protection for its lead assets, thereby safeguarding its innovations in drug delivery and therapeutic formulations.
Innovation in Drug Formulations and Delivery
At the core of Silo Pharma's strategy is the development of novel drug delivery systems. Its innovative approach encompasses:
- The use of intranasal formulations which provide a convenient and rapid therapeutic option for stress-related disorders.
- Advanced polymer-based implants ensuring sustained and controlled drug release, which is critical for chronic conditions such as fibromyalgia.
- Exploration of dual-action pharmacological approaches combining different receptor targets to enhance therapeutic efficacy without compromising safety.
Market Position and Operational Philosophy
Although Silo Pharma operates at a developmental stage, its scientifically rigorous and research-driven approach places it strategically within the biopharmaceutical industry. The company prioritizes collaborations with leading research institutions and maintains a strong emphasis on ensuring that its technologies meet regulatory safety profiles. This methodical progression from preclinical research through to clinical evaluation highlights its commitment to developing treatments that have the potential to transform patient care in areas with limited therapeutic options.
Commitment to Research Excellence
Silo Pharma is anchored on principles of expertise, authoritativeness, and trustworthiness. Its research is designed to resolve significant medical challenges with precise, mechanism-based therapies. By continuously enhancing its array of novel formulations and robust drug delivery systems, the company exemplifies a balanced approach, integrating rigorous scientific research with practical therapeutic solutions.
Englewood Cliffs, NJ, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Silo Pharma (OTCQB: SILO), a biopharmaceutical company focused on psychedelics for therapeutic use, reported its third quarter 2021 financial results and business updates. Key highlights include a research agreement with Columbia University for Alzheimer’s therapeutic development, a patent allowance from the U.S. Patent Office for CNS homing peptides, and DEA approval for a joint venture to deliver ketamine. The company has approximately $11 million in working capital and aims to uplist to the Nasdaq, enhancing long-term shareholder value.
Silo Pharma (OTCQB: SILO) has entered a sponsored research agreement with Columbia University to explore options for licensing Alzheimer’s therapeutic assets. Under the leadership of Dr. Christine Ann Denny, the initiative focuses on understanding molecular mechanisms linked to Alzheimer’s disease and memory retrieval. With 5.8 million Americans affected by Alzheimer’s, this collaboration aims to develop innovative treatments using psychedelic compounds, potentially providing significant improvements in cognitive health.
Silo Pharma (OTCQB: SILO) has entered a research agreement with Columbia University focused on developing treatments for Alzheimer’s disease. This partnership involves Dr. Christine Ann Denny, who studies the molecular mechanisms of memory and learning. Silo has the option to license certain assets related to this research, which aims to explore the therapeutic potential of ketamine for improving memory retrieval and addressing cognitive decline. The agreement represents a significant step in Silo's efforts to provide innovative solutions for patients suffering from Alzheimer’s and related conditions.
Silo Pharma (OTCQB: SILO) announced that its joint venture partner, Zylo Therapeutics, received DEA approval to develop Z-pod technology with Ketamine. CEO Eric Weisblum expressed optimism about creating a transdermal Ketamine therapeutic using this patented technology, which may also deliver Psilocybin in a controlled manner. This development aims to provide innovative solutions for patients suffering from depression, PTSD, Parkinson’s, and other neurological disorders. Updates on this partnership are anticipated as milestones are achieved.
Silo Pharma, Inc. (OTCQB: SILO) announced the filing of three Patent Cooperation Treaty (PCT) applications aimed at protecting its intellectual property related to the central nervous system delivery of unique anti-inflammatory therapeutics combined with psilocybin. This step is part of the company’s commitment to research and development in the biopharmaceutical space, specifically targeting conditions like depression and PTSD. The applications focus on the therapeutic potential of psychedelics and anti-inflammatory drugs, expanding possible treatment options for various neurological disorders.
On August 11, 2021, Silo Pharma (OTCQB:SILO) announced that its partner, ZYLO Therapeutics, successfully completed its first inspection with the SC Board of Pharmacy. This milestone enables progress with the Department of Health and Environmental Control towards developing a transdermal Ketamine therapeutic leveraging patented Z-Pod® technology. CEO Eric Weisblum emphasized the significance of this step, highlighting the potential for controlled, time-released delivery of Ketamine or Psilocybin.
Silo Pharma (OTCQB:SILO) announced a significant development in its product pipeline, receiving a notice of allowance for a patent from the United States Patent Office pertaining to its Central Nervous System Homing Peptide. This novel peptide aims to enhance the delivery of psychedelics, including Psilocybin, for therapeutic applications. CEO Eric Weisblum expressed optimism about expanding their intellectual property portfolio to cover markets for potential therapeutic applications, addressing conditions like depression and PTSD.
Silo Pharma, Inc. (OTCQB: SILO) will engage in a nationwide media tour on July 22, aimed at raising awareness about psychedelic medicines and their potential therapeutic benefits for conditions such as mental illness and chronic pain. Sponsored by Radio Media LLC, the tour will feature Dr. Josh Woolley, MD, PhD, discussing ongoing research in psychedelic therapy. The broadcast will reach various stations across the U.S., with recordings available on Silo Pharma's website post-event.
Silo Pharma (OTCQB: SILO) has entered into a Scientific Research Agreement with the University of Maryland, Baltimore, to investigate the efficacy of a novel peptide, ART-1, for delivering dexamethasone to treat rheumatoid arthritis. This study will utilize peptide-guided liposomes to potentially enhance the drug's efficacy and reduce toxicity. CEO Eric Weisblum emphasized the importance of this milestone for accessing a significant market and improving therapeutic targeting. The company aims to develop a technology platform adaptable for other drugs, enhancing treatment options for various conditions.
Silo Pharma has extended its exclusive option agreement with the University of Maryland, Baltimore to investigate novel joint-homing peptides aimed at treating rheumatoid arthritis. This extension allows Silo more time to evaluate a potentially transformative therapeutic platform that could enhance drug delivery for traditional and psychedelic treatments, which may improve efficacy while reducing toxicity. CEO Eric Weisblum emphasized the significance of this technology for targeted therapy delivery.
FAQ
What is the current stock price of Silo Pharma (SILO)?
What is the market cap of Silo Pharma (SILO)?
What is the core focus of Silo Pharma Inc?
How does Silo Pharma generate its revenue?
What are the key therapeutic programs of Silo Pharma?
What is unique about Silo Pharma's approach to drug delivery?
Who are Silo Pharma's research partners?
How does Silo Pharma protect its intellectual property?
What are the potential benefits of SPC-15?
In what ways does Silo Pharma demonstrate expertise in the industry?
